Dr Reddy's Laboratories Ltd.

Dr Reddy's Laboratories Ltd.

Dr Reddy's Laboratories Ltd.

Overview
Date Founded

1984

Headquarters

Door No. 8-2-337,Road No. 3,Banjara Hills,Hyderabad, Telangana 500034

Type of Company

Public

Employees (Worldwide)

23.5K

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Wholesale: Consumer Non-Durables/Sundries

Company Description

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Contact Data
Trying to get in touch with decision makers at Dr Reddy's Laboratories Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President & Chief Financial Officer

Chief Executive Officer-Branded Markets (India & Emerging Markets)

Chief Executive Officer, North America Generics

Chief Human Resource Officer & Executive Vice President

Executive Vice President & Global Head-Quality

Vice President & Head, External R&D & Global Marketing

Senior Vice President & Head of PSAI Commercial Organization

Executive Vice President & Head, Integrated Product Development Organization

Chief Operating Officer & Global Head Generics & PSAI Business

Board of Directors

Former Chief Executive Officer at Dr Reddy's Laboratories Ltd.

Chief Executive Officer at Dr. Reddy's Laboratories, Inc.

Executive Director & Group Chief Financial Officer at Mahindra Group

Former Head, Asian, Middle Eastern & Latin American Practices at McKinsey & Co., Inc.

Industry Advisor at KKR India LLC

Chief Executive Officer at JPMorgan India Pvt Ltd.

President at TiE Silicon Valley

Executive Chairman at Corporate & Economic Research Group Advisory Pvt Ltd.

Affiliate Professor, Department of Biochemistry at University of Washington

Former Senior Partner at McKinsey & Co., Inc.

Paths to Dr Reddy's Laboratories Ltd.
Potential Connections via
Relationship Science
You
Dr Reddy's Laboratories Ltd.
Owners & Shareholders
Details Hidden

CFSAMA manages funds across a diverse range of domestic and global asset classes, including Australian and global equities (such as global listed infrastructure and property securities), cash, fixed interest and credit. The firm's key strategies are global listed infrastructure and global property securities. For global listed infrastructure, their investment process utilizes an active, bottom-up security selection process that aims to exploit market inefficiencies. They target undervalued securities where the market underestimates the level and quality of sustainable free cash flows. The firm looks for companies with robust business models and strong management execution. For global property securities, the investment process is primarily focused on bottom-up stock research. CFSAMA focuses on undervalued real estate securities with sound qualitative attributes and sustainable earnings growth. Securities are then ranked within each region according to valuation and qualitative measures. The investment team of regional specialists undertakes rigorous research process and proprietary valuation techniques identifying mispriced opportunities in a risk-adjusted framework in order to achieve outperformance objectives. Focused research effort in real estate markets that are under-researched provides further opportunities to add value to portfolios. A great deal of emphasis is placed on meetings with individual companies in order to help identify undervalued securities.

Details Hidden

RBC GAM-UK employs fundamental analysis and quantitative analysis. Individual portfolio managers may emphasize one method of security analysis over another in providing investment management services to discretionary clients and recommendations to nondiscretionary clients. The firm's investment teams are responsible for researching investment opportunities, and implementing their findings and views on specific issuers in the management of clients' portfolios. RBC GAM-UK employs various investment strategies through our investment mandates that are based on the objectives and strategies of the clients involved. Client portfolios with similar investment mandates, strategies and guidelines are generally managed similarly. Their investment management teams continuously research available investment opportunities using fundamental and quantitative methods, including environmental, social and governance (ESG) factors. The portfolio managers consider the investment opportunities available and make an active investment decision focusing on each client account's needs, as reflected in each account's governing documents.

Details Hidden

ABSLAMC is a long-term, fundamental research-based investor which manages portfolios invested in equity, fixed-income and money-market instruments across regions and sectors. These assets are available via a wide range of financial vehicles including diversified or sector specific equity funds, fund of funds, hybrid and monthly income funds, debt and treasury products and offshore funds. These funds can be actively or passively managed. The firm's equity fund invests in stocks/equity shares of companies of different market capitalization. These funds can be actively or passively managed. Their debt mutual fund invests in a mix of debt investments such as treasury bills, government securities (G-Secs), corporate bonds and other money market instruments of varying maturities that seek to provide investors capital preservation and regular income. ABSLAMC's hybrid fund invests in a mix of growth oriented equity, capital preserving debt and other assets related instruments, which can vary proportionally over time or remain fixed.

Recent Transactions
Details Hidden

Genomma Lab Internacional SAB de CV, Genomma Lab USA, Inc. purchase Dr. Reddy's Laboratories Ltd. /Bufferin Brand from Dr Reddy's Laboratories Ltd.

Details Hidden

Dr Reddy's Laboratories Ltd. purchases Imperial Credit Pvt. Ltd.

Details Hidden

Dr Reddy's Laboratories Ltd. purchases Ducere Pharma LLC/Otc Bus from Ducere Pharma LLC

Transaction Advisors
Accountant

Advised onStumpp Schuele & Somappa Ltd purchases Compact Electric Ltd from Dr Reddy's Laboratories Ltd.

Underwriter

Advised onDr Reddy's Laboratories Ltd. issued American Depositary Shares

Legal Advisor

Advised onDr Reddy's Laboratories Ltd. issued American Depositary Shares

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Clients

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Encore Dermatology, Inc. manufactures prescription therapies and medical devices for dermatologists. It offers hylatopicplus emollient foam, hylatopicplus cream, and tetrix cream to manage and relieve the burning, itching, and pain. The company was founded Robert J. Moccia and Michael Brown in 2015 and is headquartered in Malvern, PA.

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Key Stats and Financials As of 2018
Market Capitalization
$478B
Total Enterprise Value
$376B
Earnings Per Share
$59.13
Revenue
$142B
Net Profit
$9.81B
EBITDA
$22.9B
EBITDAMargin
16.12%
Total Debt
$50.7B
Total Equity
$126B
Enterprise Value Sales
2.65x
Enterprise Value EBITDAOperating
16.41x
TEVNet Income
38.31x
Debt TEV
0.14x
Three Year Compounded Annual Growth Rate Of Revenue
-1.41%
Five Year Compounded Annual Growth Rate Of Revenue
4.08%
Investments
Details Hidden

Perlecan Pharma Pvt Ltd. provides research and development for new drugs. The company is headquartered in Hyderabad, India

Suppliers
NATCO Pharma Ltd. Pharmaceuticals | Hyderabad, TS

NATCO Pharma Ltd. engages in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations is a leading player in India's oncology segment with 28 active brands. The International Formulations is a portfolio of niche and complex products for the U.S. market. The Active Pharmaceutical Ingredients is strategically important division. The company was founded by Venkaiah Chowdary Nannapaneni on September 19, 1981 and is headquartered in Hyderabad, India.

Ess Dee Aluminium Ltd. Paper Products | Mumbai, MA

Ess Dee Aluminium Ltd. engages in the manufacture of primary packaging materials for pharmaceutical, food, and fast-moving consumer goods industries. It specializes in cold form blister and child-resistant-blister packaging. Its products include aseptic, bubble, bliss, curative, invasive, and others. The company was founded in 1991 and is headquartered in Mumbai, India.

HSIL Ltd. Wholesale: Consumer Durables | Gurgaon, HA

HSIL Ltd. engages in manufacturing, selling, and trading of glass, building, plastic, and consumer products. It operates through the following segments: Building Products, Consumer Products, Packaging Products, Retail Business, and Others. The company was founded on February 8, 1960 and is headquartered in Gurgaon, India.

Competitors
Sun Pharmaceutical Industries Ltd. Pharmaceuticals - Mumbai, MA

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Divi's Laboratories Ltd. Pharmaceuticals - Hyderabad, TS

Established in the year 1990, with Research & Development as its prime fundamental, Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry. With five years of experience, expertise and a proven track-record of helping many companies with its turn-key and consulting strengths, Divis Laboratories established its first manufacturing facility in 1995. Built on a 500 acre site at Hyderabad (Unit-I). the plant comprises of 13 multi-purpose production blocks and has space for further growth and expansion. Divis Laboratories set up its second manufacturing facility at Visakhapatnam (Unit-II). in the year 2002 on a 350 acre site. The site has 14 multi purpose production blocks.

Thermo Fisher Scientific, Inc. Industrial Machinery & Manufacturing - Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Dr Reddy's Laboratories Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Dr Reddy's Laboratories Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Dr Reddy's Laboratories Ltd..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/dr-reddys-laboratories-ltd-57040
  • https://relationshipscience.com/organization/dr-reddys-laboratories-ltd-57040